Clinical Trial

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Study acronym: PRESERVE-004
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-06-30; most recent amendment 2026-04-08.
Status change: Recruiting → Active, Not Recruiting 2024-10-22
Status change: Not Yet Recruiting → Recruiting 2022-12-26
Trial Details
NCT Number NCT05446298
Lead Sponsor OncoC4, Inc.
Collaborators: Merck Sharp & Dohme LLC, GOG Foundation
Conditions Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Enrollment 58 participants
Start Date 2022-12-22
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-13